Financials data is unavailable for this security.
View more
Year on year Lotus Pharmaceuticals Inc 's net income fell -12.22% from 16.43m to 14.42m despite revenues that grew 28.71% from 56.48m to 72.70m. An increase in the selling, general and administrative costs as a percentage of sales from 17.97% to 22.23% was a component in the falling net income despite rising revenues.
Gross margin | 35.10% |
---|---|
Net profit margin | 2.45% |
Operating margin | 1.14% |
Return on assets | 1.55% |
---|---|
Return on equity | 1.81% |
Return on investment | 1.71% |
More ▼
Cash flow in USDView more
In 2010, cash reserves at Lotus Pharmaceuticals Inc fell by 2.61m. However, the company earned 26.78m from its operations for a Cash Flow Margin of 36.83%. In addition the company used 29.45m on investing activities and also paid in financing cash flows.
Cash flow per share | 0.1397 |
---|---|
Price/Cash flow per share | 2.65 |
Book value per share | 3.58 |
---|---|
Tangible book value per share | 1.76 |
More ▼
Balance sheet in USDView more
Current ratio | 0.5322 |
---|---|
Quick ratio | 0.4428 |
Total debt/total equity | 0.0544 |
---|---|
Total debt/total capital | 0.0516 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items dropped -18.49%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years) | 42.39 |
---|---|
EPS (TTM) vs TTM 1 year ago | -92.81 |